[1]李光尧.重组人促红细胞生成素联合还原型谷胱甘肽对尿毒症贫血患者贫血指标及氧化应激反应的影响[J].医学信息,2023,36(19):156-159.[doi:10.3969/j.issn.1006-1959.2023.19.035]
　LI Guang-yao.Effect of Recombinant Human Erythropoietin Combined with Reduced Glutathione on Anemia Index and Oxidative Stress Response in Patients with Uremia Anemia[J].Journal of Medical Information,2023,36(19):156-159.[doi:10.3969/j.issn.1006-1959.2023.19.035]
点击复制

重组人促红细胞生成素联合还原型谷胱甘肽对尿毒症贫血患者贫血指标及氧化应激反应的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年19期
页码:
156-159
栏目:
药物与临床
出版日期:
2023-10-01

文章信息/Info

Title:
Effect of Recombinant Human Erythropoietin Combined with Reduced Glutathione on Anemia Index and Oxidative Stress Response in Patients with Uremia Anemia
文章编号:
1006-1959（2023）19-0156-04
作者:
李光尧
（余干楚东医院肾内科，江西 余干 335100）
Author(s):
LI Guang-yao
(Department of Nephrology,Yugan Chudong Hospital,Yugan 335100,Jiangxi,China)
关键词:
重组人促红素注射液; 还原型谷胱甘肽; 尿毒症; 贫血; 氧化应激反应
Keywords:
Recombinant human erythropoietin injection; Reduced glutathione; Uremia; Anemia; Oxidative stress reaction
分类号:
R692.5
DOI:
10.3969/j.issn.1006-1959.2023.19.035
文献标志码:
A
摘要:
目的 研究重组人促红细胞生成素（rhEPO）联合还原型谷胱甘肽（GSH）对尿毒症贫血患者贫血指标及氧化应激反应的影响。方法 以2020年1月-2022年3月余干楚东医院收治的70例尿毒症贫血患者为研究对象，按照随机数字表法分为对照组（35例）与观察组（35例）。两组均接受血液透析治疗，对照组另给予rhEPO治疗，观察组在其基础上联合GSH治疗，比较两组贫血疗效、贫血指标[红细胞计数（RBC）、红细胞比容（HCT）、血红蛋白（Hb）]、氧化应激指标[超氧化物歧化酶（SOD）、丙二醛（MDA）]、营养指标[血浆白蛋白（TP）、血清转铁蛋白（TRF）]、不良反应。结果 观察组贫血治疗有效率高于对照组（P＜0.05）；两组治疗后RBC、HCT、Hb指标高于治疗前，且观察组RBC、Hb、HCT指标高于对照组（P＜0.05）；两组治疗后SOD指标高于治疗前，MDA指标低于治疗前，且观察组SOD高于对照组，MDA低于对照组（P＜0.05）；两组治疗后TP、TRF水平高于治疗前，且观察组TP、TRF水平高于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 rhEPO联合GSH具有良好的贫血治疗效果，可纠正尿毒症贫血患者的贫血指标，减轻其氧化应激反应，改善其营养状态，且不良反应少。
Abstract:
Objective To study the effect of recombinant human erythropoietin (rhEPO) combined with reduced glutathione (GSH) on anemia index and oxidative stress in patients with uremic anemia.Methods A total of 70 patients with uremic anemia admitted to Yugan Chudong Hospital from January 2020 to March 2022 were selected as research objects, and they were divided into control group (35 patients) and observation group (35 patients) by random number table method. Both groups received hemodialysis treatment, the control group was treated with rhEPO, and the observation group was treated with GSH on the basis of the control group. The anemia efficacy, anemia indicators [red blood cell count (RBC), hematocrit (HCT), hemoglobin (Hb)], oxidative stress indicators [superoxide dismutase (SOD), malondialdehyde (MDA)], nutritional indicators [plasma albumin (TP), serum transferrin (TRF)], adverse reactions were compared between the two groups.Results The effective rate of anemia treatment in the observation group was higher than that in the control group (P<0.05). The levels of RBC, HCT and Hb in the two groups after treatment were higher than those before treatment, and the levels of RBC, Hb and HCT in the observation group were higher than those in the control group (P<0.05). The level of SOD in the two groups after treatment was higher than that before treatment, and the level of MDA was lower than that before treatment, while the level of SOD in the observation group was higher than that in the control group, and the level of MDA was lower than that in the control group (P<0.05). After treatment, the levels of TP and TRF in the two groups were higher than those before treatment, and the levels of TP and TRF in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion rhEPO combined with GSH has a good therapeutic effect on anemia, which can correct the anemia index of uremic anemia patients, reduce their oxidative stress reaction, improve their nutritional status, and have fewer adverse reactions.

参考文献/References:

[1]孙蔚倩,佟怡婧,唐余燕,等.罗沙司他与重组人促红细胞生成素对维持性血液透析患者肾性贫血治疗的疗效比较[J].国际泌尿系统杂志,2022,42(5):867-871.[2]奚希相,马金苗,徐震宇.还原型谷胱甘肽治疗脓毒症急性肾损伤的效果[J].中国医药导报,2022,19(9):83-86.[3]肖佳,刘书馨,张爽.罗沙司他对促红细胞生成素抵抗的维持性血液透析患者炎症因子的影响[J].中国实用内科杂志,2021,41(12):1061-1063.[4]刘旭,曲珍吉姆,刘文虎,等.高原地区尿毒症患者通过综合治疗改善贫血的研究[J].临床和实验医学杂志,2020,19(1):95-98.[5]方蕾,黄扬扬,伍学琪.罗沙司他与重组人促红素治疗维持性血液透析患者肾性贫血的效果[J].中国医药导报,2021,18(11):137-140.[6]谢萍,张苇,孙萍.血液透析联合rHuEPO对尿毒症贫血患者Hb、Hct水平的影响[J].河北医药,2021,43(2):243-245,249.[7]杨帆,童婧涵,李会,等.还原型谷胱甘肽联合高通量血液透析对急性肾损伤患者血清CysC、KIM-1及SCr的影响[J].西部医学,2020,32(6):863-867.[8]李娟,何娟,毛恩强,等.还原型谷胱甘肽对重症患者使用万古霉素致药物性肾损伤的保护作用[J].中华危重病急救医学,2020,32(7):819-823.[9]李东峰,王冬梅.rhEPO联合左卡尼汀治疗对尿毒症患者血清内皮素及心功能的影响[J].中国医师杂志,2020,22(11):1744-1746.[10]李昌艳,刘娟,顾芳,等.静脉输注蔗糖铁联合重组人促红细胞生成素对维持血液透析肾性贫血患者的疗效与安全性分析[J].解放军医药杂志,2020,32(2):51-55.[11]何丹,贾德昭,涂小琼,等.还原型谷胱甘肽对小儿肾小球肾炎血清IGF-Ⅱ和GM-CSF水平的影响[J].河北医药,2020,42(4):594-597.[12]孙凌霜,薛瑾虹,魏萌,等.罗沙司他替代大剂量重组人红细胞生成素治疗维持性血液透析患者贫血的疗效[J].肾脏病与透析肾移植杂志,2021,30(3):217-221.[13]Giannikouris I.The effect of N-acetylcysteine on oxidative serum biomarkers of hemodialysis patients[J].Hippokratia,19(2):131-135.[14]骆玉璇.还原型谷胱甘肽对化疗相关性肾损伤患者肾损伤标志物的影响及意义[J].中国卫生检验杂志,2020,30(3):260-262,267.[15]马遥,孙晓丹,彭彦平,等.EPO联合左卡尼汀对老年尿毒症透析患者营养状态及生活质量的影响[J].中国医师杂志,2020,22(1):116-119.[16]张靖华,王长安,黑小杰.还原型谷胱甘肽联合重组人促红素治疗尿毒症贫血患者的有效性与安全性[J].药物评价研究,2017,40(10):1464-1467.[17]林辉.左卡尼汀联合重组人促红细胞生成素治疗血液透析患者肾性贫血效果观察[J].浙江医学,2019,41(15):1665-1666,1672.[18]饶毅峰,朱平,何川鄂,等.重组人促红细胞生成素对血液透析患者营养状况和免疫功能的影响[J].现代生物医学进展,2017,17(15):2888-2891.[19]李晓燕,冯要菊.左卡尼汀联合促红细胞生成素纠正维持性血液透析患者肾性贫血的效果及对内皮素和左室重构的影响[J].药物评价研究,2017,40(4):521-524.[20]张勇,侯娟.左卡尼汀联合促红细胞生成素治疗肾性贫血的疗效分析[J].临床肾脏病杂志,2018,18(3):176-179.[21]赵娜,郭一丹,张春霞,等.重组人促红素联合左卡尼汀对老年血液透析患者肾性贫血治疗效果及氧化应激的影响[J].临床误诊误治,2021,34(4):33-38.[22]Wang H,Du YS,Xu WS,et al.Exogenous glutathione exerts a therapeutic effect in ischemic stroke rats by interacting with intrastriatal dopamine[J].Chinese Journal of Pharmacology,2022,43(3):541-551.[23]夏璐,张小玲.还原型谷胱甘肽联合连续性血液净化治疗急性肾损伤的疗效分析[J].中国临床医生杂志,2020,48(2):177-181.

更新日期/Last Update: 1900-01-01